Jul. 17 at 6:46 PM
$CRDL You are 100% correct "ElieoG" =All things are trending towards our long awaited plan and end game: The AHA stamp of approval from the peers & medical comminity, the completed Maveric 3 enrollment, and then the trial's data lock November / December and subsequent results published. These current volume jumps are the larger groups / sideline waiters and insitutions that now have the greenlight to buy now that AHA has added the long awaited credibility to the program. The s/p will still fluctuate, but hold. Once these catalysts start seeing daylight, the aggression to
$2 -
$3 u.s. can happen rapidly. Once that new floor foundation is comfortable at 2, 3, 4 dollars, the new data, the immidiate FDA application, and the potential partnership / suitor's chatter, ... will make the s/p explosive and expensive very quickly.
